Advances in immunotherapy for tuberculosis treatment.

[1]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[2]  R. Maizels,et al.  Helminth immunoregulation: The role of parasite secreted proteins in modulating host immunity , 2009, Molecular and biochemical parasitology.

[3]  Y. Kaneda,et al.  Novel prophylactic and therapeutic vaccine against tuberculosis. , 2009, Vaccine.

[4]  Alimuddin Zumla,et al.  Tuberculosis -A comprehensive Clinical reference , 2009 .

[5]  Alimuddin Zumla,et al.  Tuberculosis due to high-dose challenge in partially immune individuals: a problem for vaccination? , 2009, The Journal of infectious diseases.

[6]  G. Victora,et al.  Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients , 2009, Cancer Gene Therapy.

[7]  S. Mello,et al.  Comprehensive gene expression profiling in lungs of mice infected with Mycobacterium tuberculosis following DNAhsp65 immunotherapy , 2009, The journal of gene medicine.

[8]  J. Ravetch,et al.  Identification of a receptor required for the anti-inflammatory activity of IVIG , 2008, Proceedings of the National Academy of Sciences.

[9]  V. M. Frolov,et al.  Cytokine profiles of HIV patients with pulmonary tuberculosis resulting from adjunct immunotherapy with herbal phytoconcentrates Dzherelo and Anemin. , 2008, Cytokine.

[10]  J. Adams,et al.  IL-15 Links TLR2/1-Induced Macrophage Differentiation to the Vitamin D-Dependent Antimicrobial Pathway , 2008, The Journal of Immunology.

[11]  M. Gómez-Lim,et al.  Transgenic tomato expressing interleukin‐12 has a therapeutic effect in a murine model of progressive pulmonary tuberculosis , 2008, Clinical and experimental immunology.

[12]  J. Bayona,et al.  Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible , 2008, PloS one.

[13]  G. Kutsyna,et al.  Effect of oral immunomodulator Dzherelo in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS. , 2008, International immunopharmacology.

[14]  S. Jolles,et al.  Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. , 2008, Tuberculosis.

[15]  Robert M. Anthony,et al.  Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc , 2008, Science.

[16]  S. Ehlers,et al.  Mycobacterium tuberculosis prevents inflammasome activation. , 2008, Cell host & microbe.

[17]  B. Strober,et al.  An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast* , 2008 .

[18]  H. Cai,et al.  Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83 , 2008, Gene Therapy.

[19]  M. O'Donnell,et al.  Improved Protection against Disseminated Tuberculosis by Mycobacterium bovis Bacillus Calmette-Guérin Secreting Murine GM-CSF Is Associated with Expansion and Activation of APCs1 , 2007, The Journal of Immunology.

[20]  J. Keane,et al.  T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. , 2007, Immunity.

[21]  Matthew S. Cook,et al.  Immunodominant Tuberculosis CD8 Antigens Preferentially Restricted by HLA-B , 2007, PLoS pathogens.

[22]  G. Rook,et al.  Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? , 2007, The Journal of infectious diseases.

[23]  S. Bae,et al.  Pulmonary impairment after tuberculosis. , 2007, Chest.

[24]  S. Jolles,et al.  Current strategies in TB immunotherapy. , 2007, Current molecular medicine.

[25]  R. Reljic.  IFN-gamma therapy of tuberculosis and related infections. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[26]  Armando Garsd,et al.  Safety and Activity of the Immune Modulator HE2000 on the Incidence of Tuberculosis and Other Opportunistic Infections in AIDS Patients , 2007, Antimicrobial Agents and Chemotherapy.

[27]  J. Peel,et al.  Intradermal injection of heat-killed Mycobacterium vaccae in dogs with atopic dermatitis: a multicentre pilot study. , 2007, Veterinary dermatology.

[28]  J. Bramson,et al.  Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. , 2007, Vaccine.

[29]  Neel R Gandhi,et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.

[30]  A. Garsd,et al.  Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000). , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[31]  V. Rybin,et al.  cAMP synthesis and degradation by phagosomes regulate actin assembly and fusion events: consequences for mycobacteria , 2006, Journal of Cell Science.

[32]  C. Stanford,et al.  Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. , 2006, Respiratory medicine.

[33]  R. Hernández-Pando,et al.  A combination of a transforming growth factor‐β antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis , 2006, Clinical and experimental immunology.

[34]  V. Deretic,et al.  Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism , 2006, Cellular microbiology.

[35]  P. Cardona.  RUTI: a new chance to shorten the treatment of latent tuberculosis infection. , 2006, Tuberculosis.

[36]  W. Bishai,et al.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. , 2005, American journal of respiratory and critical care medicine.

[37]  S. Jolles,et al.  Therapeutic Efficacy of High-Dose Intravenous Immunoglobulin in Mycobacterium tuberculosis Infection in Mice , 2005, Infection and Immunity.

[38]  R. Wallis.  Reconsidering adjuvant immunotherapy for tuberculosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  Donald A Enarson,et al.  Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. , 2005, American journal of respiratory and critical care medicine.

[40]  J. Ellner,et al.  Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. , 2005, The Journal of infectious diseases.

[41]  Virginia Arcos,et al.  Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. , 2005, Vaccine.

[42]  L. Faccioli,et al.  Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice , 2005, Gene Therapy.

[43]  G. Rook,et al.  16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis. , 2005, The Journal of infectious diseases.

[44]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[45]  P. López-Saura,et al.  Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study , 2004, BMC infectious diseases.

[46]  John Chan,et al.  TNF Influences Chemokine Expression of Macrophages In Vitro and That of CD11b+ Cells In Vivo during Mycobacterium tuberculosis Infection1 , 2004, The Journal of Immunology.

[47]  R. Barker,et al.  Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[48]  S. Fortune,et al.  Mycobacterium tuberculosis Inhibits Macrophage Responses to IFN-γ through Myeloid Differentiation Factor 88-Dependent and -Independent Mechanisms1 , 2004, The Journal of Immunology.

[49]  K. Lee,et al.  Six-month Therapy with Aerosolized Interferon-γ for Refractory Multidrug-Resistant Pulmonary Tuberculosis , 2004, Journal of Korean medical science.

[50]  P. Haslett,et al.  Adjunctive Thalidomide Therapy for Childhood Tuberculous Meningitis: Results of a Randomized Study , 2004, Journal of child neurology.

[51]  Stuart M. Brown,et al.  Aerosolized Gamma Interferon (IFN-γ) Induces Expression of the Genes Encoding the IFN-γ-Inducible 10-Kilodalton Protein but Not Inducible Nitric Oxide Synthase in the Lung during Tuberculosis , 2004, Infection and Immunity.

[52]  John L. Johnson,et al.  A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis , 2004, AIDS.

[53]  G. Rook,et al.  Pulmonary tuberculosis in BALB/c mice with non‐functional IL‐4 genes: changes in the inflammatory effects of TNF‐α and in the regulation of fibrosis , 2004, European journal of immunology.

[54]  G. Kaplan,et al.  Mycobacterium tuberculosis Growth at theCavity Surface: a Microenvironment with FailedImmunity , 2003, Infection and Immunity.

[55]  R. Badaró,et al.  Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. , 2003, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[56]  John L. Johnson,et al.  Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[57]  A. Kolobov,et al.  Biological Activity of Peptide SCV-07 Against Murine Tuberculosis. , 2003, Russian journal of immunology : RJI : official journal of Russian Society of Immunology.

[58]  C. Orellana.  Immune system stimulator shows promise against tuberculosis. , 2002, The Lancet. Infectious diseases.

[59]  G. Orefici,et al.  Mycobacterium tuberculosis subverts the differentiation of human monocytes into dendritic cells , 2002, European journal of immunology.

[60]  Alimuddin Zumla,et al.  Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial , 2002, The Lancet.

[61]  G. Rook,et al.  Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells , 2002, Nature Medicine.

[62]  G. Kaplan,et al.  Use of IMiD3, a Thalidomide Analog, as an Adjunct to Therapy for Experimental Tuberculous Meningitis , 2002, Antimicrobial Agents and Chemotherapy.

[63]  P. Sonnenberg,et al.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers , 2001, The Lancet.

[64]  JoAnne L. Flynn,et al.  Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology , 2001, Infection and Immunity.

[65]  P. Haslett,et al.  Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role , 2000, Journal of child neurology.

[66]  G. Rook,et al.  Interactions between hormone‐mediated and vaccine‐mediated immunotherapy for pulmonary tuberculosis in BALB/c mice , 2000, Immunology.

[67]  Alan D. Roberts,et al.  Lack of Protection in Mice and Necrotizing Bronchointerstitial Pneumonia with Bronchiolitis in Guinea Pigs Immunized with Vaccines Directed against the hsp60 Molecule ofMycobacterium tuberculosis , 2000, Infection and Immunity.

[68]  John L. Johnson,et al.  Randomized Controlled Trial of Mycobacterium vaccae Immunotherapy in Non-Human Immunodeficiency Virus-Infected Ugandan Adults with Newly Diagnosed Pulmonary Tuberculosis , 2000 .

[69]  S. Giosué,et al.  Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. , 2000, European cytokine network.

[70]  J. Meer,et al.  Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. , 2000, The Journal of infectious diseases.

[71]  S. Lu,et al.  [Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis]. , 2000, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[72]  Gerene M. Denning,et al.  Inhibition of Ca2+ Signaling by Mycobacterium tuberculosisIs Associated with Reduced Phagosome–Lysosome Fusion and Increased Survival within Human Macrophages , 2000, The Journal of experimental medicine.

[73]  L. Corral,et al.  Immunomodulation by thalidomide and thalidomide analogues , 1999, Annals of the rheumatic diseases.

[74]  Elson,et al.  Onchocerciasis modulates the immune response to mycobacterial antigens , 1999, Clinical and experimental immunology.

[75]  K. Moelling,et al.  Therapy of tuberculosis in mice by DNA vaccination , 1999, Nature.

[76]  R. North.  Mice incapable of making IL‐4 or IL‐10 display normal resistance to infection with Mycobacterium tuberculosis , 1998, Clinical and experimental immunology.

[77]  G. Kaplan,et al.  Differential Gene Expression in Response to Adjunctive Recombinant Human Interleukin-2 Immunotherapy in Multidrug-Resistant Tuberculosis Patients , 1998, Infection and Immunity.

[78]  G. Kaplan,et al.  A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. , 1998, The Journal of infectious diseases.

[79]  M. Burdick,et al.  Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis , 1997, Infection and immunity.

[80]  J. Watson,et al.  Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis , 1997, Infection and immunity.

[81]  W. Rom,et al.  Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol , 1997, The Lancet.

[82]  Gilla Kaplan,et al.  Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity , 1996, Molecular medicine.

[83]  R. Dewar,et al.  The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[84]  C. Lowenstein,et al.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. , 1995, Immunity.

[85]  W. Rom,et al.  Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis , 1995, Molecular medicine.

[86]  Dinakar,et al.  T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. , 1994, The Journal of clinical investigation.

[87]  R. Dwek,et al.  Agalactosyl glycoforms of IgG autoantibodies are pathogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Grange.  Immunotherapy of tuberculosis. , 1990 .

[89]  N. Horne.  Prednisolone in Treatment of Pulmonary Tuberculosis: A Controlled Trial , 1960, British medical journal.

[90]  C. Jagannath,et al.  Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis. , 2008, Tuberculosis.

[91]  Wang Li.  Adjuvant Effect of Mycobacterium Vaccae on Treatment of Recurrent Treated Pulmonary Tuberculosis:A Meta-analysis , 2007 .

[92]  A. Kelso,et al.  Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. , 2006, Cancer research.

[93]  Y. Luo.  [The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis]. , 2001, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[94]  S. Bilaçeroğlu,et al.  Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[95]  G. Kaplan,et al.  Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis. , 1998, Novartis Foundation symposium.

[96]  G. Kaplan,et al.  rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[97]  G. Bahr,et al.  A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy. , 1994, Immunology.